Use of aceclofenac (Aertal) in early stages arthrosis of the knee joint

Cover Page

Cite item

Full Text

Abstract

The purpose of this study was in the assessment of the efficacy and safety of Aertal® in patients with knee OA in its early stages. The study group consisted of patients with gonarthrosis stage I-II. Representative group consisted of 80 patients (43 women and 37 men), mean age was 58 years. All subjects were randomized to conservative treatment groups (A and B). Patients received either Aertal® 100 mg 2 times a day, or diclofenac 75 mg 2 times a day for 6 weeks. The average value of the visual analogue scale (VAS) for pain intensity estimates in group A was 7.4, group B - 7.6. After 6 weeks of conservative therapy VAS index fell to 3.8 in group A and 5,4 - in group B, showing a significant reduction in pain intensity. The Western Ontario McMaster (WOMAC) index in group A was 31,68±12,41 (>40), in the group B 36,17±10,32 (>40). Similarly, the WOMAC index fell to 6.28 in group A and to 19.42 - in group B, which shows a significant decrease of difficulty in daily physical activities, including improving the quality of life of patients. The results of this study showed a favorable safety profile in the group B (Aertal®) compared with group A (diclofenac), against the background of almost equivalent efficacy of both groups. Thus Aertal® has much better gastrointestinal tolerability than diclofenac. Based on the data, it can be stated that the key issue in choosing NSAID orthopedic surgeon is its high clinical efficacy, safety, and well-tolerated.

About the authors

N. V Zagorodniy

People’s Friendship University of Russia; City Clinical Hospital №31 of the Department of Health of Moscow

д-р мед. наук, проф. каф. травматологии и ортопедии Медицинского института ФГАОУ ВО РУДН; ГБУЗ ГКБ №31 117198, Russian Federation, Moscow, ul. Miklukho-Maklaya, d. 6; 119415, Russian Federation, Moscow, ul. Lobachevskogo, d. 42

A. N Ivashkin

People’s Friendship University of Russia; City Clinical Hospital №31 of the Department of Health of Moscow

д-р мед. наук, проф. каф. травматологии и ортопедии Медицинского института ФГАОУ ВО РУДН; ГБУЗ ГКБ №31 117198, Russian Federation, Moscow, ul. Miklukho-Maklaya, d. 6; 119415, Russian Federation, Moscow, ul. Lobachevskogo, d. 42

A. R Zakirova

People’s Friendship University of Russia; City Clinical Hospital №31 of the Department of Health of Moscow

Email: arthro@mail.ru
канд. мед. наук, доц. каф. травматологии и ортопедии Медицинского института ФГАОУ ВО РУДН; ГБУЗ ГКБ №31 117198, Russian Federation, Moscow, ul. Miklukho-Maklaya, d. 6

T. O Skipenko

People’s Friendship University of Russia; City Clinical Hospital №31 of the Department of Health of Moscow

канд. мед. наук, доц. каф. травматологии и ортопедии Медицинского института ФГАОУ ВО РУДН; ГБУЗ ГКБ №31 117198, Russian Federation, Moscow, ul. Miklukho-Maklaya, d. 6; 119415, Russian Federation, Moscow, ul. Lobachevskogo, d. 42

References

  1. Naoshi F, Yoshinari M, Masahiro N et al. Zonal gene expression of chondrocytes in osteoarthritic cartilage. Arthritis Rheum 2008; 58 (12): 3843-53.
  2. Ogata Y, Mabuchi Y, Yoshida M et al. Purified Human Synovium Mesenchymal Stem Cells as a Good Resource for Cartilage Regeneration. PLoS ONE 2015; 10 (6).
  3. Matsukura Y, Muneta T, Tsuji K et al. Mouse synovial mesenchymal stem cells increase in yield with knee inflammation. J Orthop Res 2015; 33: 246-53.
  4. Berenbaum F. Osteoarthritis as an inflammatory disease (osteoarthritis is not osteoarthrosis!). Osteoarthritis Cartilage 2013; 21: 16-21. doi: 10.1016/j.joca.2012.11.012.
  5. Jakobsen R.B, Engebretsen L, Slauterbeck J.R. An Analysis of the Quality of Cartilage Repair Studies. J Bone Joint Surg Am 2014; 87 (10): 2232-9.
  6. Anthony J. Ferretti, D.O. Osteoarthritis of the Knee: Pill, Needle, or Knife. MHSA Primary Care 2015 LECOM Summer CME.
  7. Lanas A, Ferrandez A. NSAID-induced gastrointestinal damage: current clinical management and recommendations for prevention. Chin J Dig Dis 2006; 7 (3): 127-33.
  8. Ward D.E, Veys E.M, Bowdker J.M, Roma J. Comparison of aceclofenac with diclofenac in the treatment of osteoarthrosis. Clin Rheumatol 1995; 14: 656-62.
  9. Somashekar P.L, Sanjay Pai P.N, Gopalkrishna Rao. Synthesis and Characterization of Specified Impurities of Aceclofenac. Chem Sci Trans 2013; 2 (3): 813-20.
  10. Brandt K.D. The mechanism of action of nonsteroidal anti - inflammatory drugs. J Rheum 1991; 18: 120-1.
  11. Чичасова Н.В. Лечение остеоартроза: влияние на хрящевую ткань различных противовоспалительных препаратов. Рус. мед. журн. 2005; 13 (8): 539-43.
  12. Hаskinsson E.C, Irani M, Murray F. A large prospective open - label, multi - centre SAMM study, comparing the safety of aceclofenac with diclofenac in patients with rheumatic disease. Eur J Rheumatol Inflam 2000; 17: 1-7.
  13. Dooley M, Spencer C.M, Dunn C.J et al. Aceclofenac. A reappraisal of its use in the management of pain and rheumatic disease. Drugs 2001; 61 (9): 1351-78.
  14. Pasero G, Ruju G, Macolongo R et al. Aceclofenac versus naproхen in the treatment of ankylosing spondylitis: a double - blend, controlled study. Curr Nher Res 1994; 55: 833-42.
  15. Perez Busquiner M, Calero E, Rodriguez M et al. Comparison of aceclofenac with piroxicam in the treatment of osteosrthrosis. Clin Rheumatol 1997; 16: 154-9.
  16. Ward D.E, Veys E.M, Bowdler J.M, Roma J. Comparison of aceclofenac with diclofenac in the treatment of osteoarthritis. Clin Rheumatol 1995; 14 (6): 656-62.
  17. Lemmel E.M, Leeb B, De Bast J, Aslanidis S. Patient and physician satisfaction with aceclofenac: results of the European Observational Cohort Study (experience with aceclofenac for inflammatory pain in daily practice). Aceclofenac is the treatment of choice for patients and physicians in the management of inflammatory pain. Curr Med Res Opin 2002; 18 (3): 146-53.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2016 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Согласие на обработку персональных данных

 

Используя сайт https://journals.rcsi.science, я (далее – «Пользователь» или «Субъект персональных данных») даю согласие на обработку персональных данных на этом сайте (текст Согласия) и на обработку персональных данных с помощью сервиса «Яндекс.Метрика» (текст Согласия).